154 related articles for article (PubMed ID: 32453217)
1. Benralizumab as a Potential Adjunctive Therapy in Eosinophilic Granulomatosis With Polyangiitis.
Lee Y; Hojjati M
J Clin Rheumatol; 2021 Dec; 27(8S):S401-S402. PubMed ID: 32453217
[No Abstract] [Full Text] [Related]
2. Benralizumab in eosinophilic granulomatosis with polyangiitis.
Laorden D; Romero D; Domínguez-Ortega J
Med Clin (Barc); 2022 May; 158(9):441-442. PubMed ID: 34728088
[No Abstract] [Full Text] [Related]
3. Successful concomitant therapy with mepolizumab and dupilumab for atypical eosinophilic granulomatosis with polyangiitis.
Anai M; Yoshida C; Ozono K; Furukawa H; Ishimaru Y; Sakata S; Saruwatari K; Muramoto K; Tomita Y; Saeki S; Ichiyasu H; Sakagami T
Allergol Int; 2022 Apr; 71(2):259-261. PubMed ID: 35074267
[No Abstract] [Full Text] [Related]
4. Mepolizumab to treat eosinophilic granulomatosis with polyangiitis.
Callejas Rubio JL; Moreno Higueras M; Ortego Centeno N
Med Clin (Barc); 2024 Feb; 162(3):140. PubMed ID: 37567822
[No Abstract] [Full Text] [Related]
5. Mepolizumab in patients with eosinophilic granulomatosis with polyangiitis in remission: What is the right dose?
Akdime F; Puéchal X; Roche N
J Allergy Clin Immunol Pract; 2021 Jul; 9(7):2942-2943. PubMed ID: 34246444
[No Abstract] [Full Text] [Related]
6. Eosinophilic granulomatosis with polyangiitis evolution during severe eosinophilic asthma treatment with benralizumab.
Hočevar A; Kopač P; Rotar Ž; Novljan MP; Škrgat S
J Allergy Clin Immunol Pract; 2020; 8(7):2448-2449. PubMed ID: 32304835
[No Abstract] [Full Text] [Related]
7. Two pediatric cases of ANCA-negative eosinophilic granulomatosis with polyangiitis successfully treated with dupilumab.
Galant-Swafford J; Geng B; Leibel S; Akuthota P; Tucker S; Cernelc-Kohan M; Sheets R; Nation J; Jefferson AA
J Allergy Clin Immunol Pract; 2020; 8(10):3643-3646.e1. PubMed ID: 32668296
[No Abstract] [Full Text] [Related]
8. Reduction in ANCA levels associated with mepolizumab add-on treatment in eosinophilic granulomatosis with polyangiitis: Case series and literature review.
Kamide Y; Watai K; Nakamura Y; Iwata M; Fukutomi Y; Taniguchi M; Sekiya K
Allergol Int; 2024 Jan; 73(1):180-183. PubMed ID: 37852914
[No Abstract] [Full Text] [Related]
9. Eosinophilic granulomatosis with polyangiitis successfully treated with benralizumab.
Chica-Guzmán MV; Morillo-Guerrero R; Carrón-Herrero A; González-de-Olano D; Almonacid-Sánchez C
Ann Allergy Asthma Immunol; 2020 Aug; 125(2):228-230. PubMed ID: 32407950
[No Abstract] [Full Text] [Related]
10. Benralizumab: A novel treatment for the cutaneous features of paediatric eosinophilic granulomatosis with polyangiitis (pEGPA).
Bandla M; Howard M; McNally A; Armstrong D; Simpson I; Mar A
Australas J Dermatol; 2023 Aug; 64(3):404-407. PubMed ID: 37195732
[TBL] [Abstract][Full Text] [Related]
11. Eosinophilic granulomatosis with polyangiitis (formerly Churg-Strauss syndrome): where are we now?
Groh M; Pagnoux C; Guillevin L
Eur Respir J; 2015 Nov; 46(5):1255-8. PubMed ID: 26521277
[No Abstract] [Full Text] [Related]
12. Successful benralizumab for eosinophilic myocarditis in eosinophilic granulomatosis with polyangiitis.
Belfeki N; Abroug S; Ghriss N; Chouchane I; Hamrouni S; Strazzulla A; Zayet S
Clin Exp Rheumatol; 2021 Oct; 40(4):834-837. PubMed ID: 35522541
[TBL] [Abstract][Full Text] [Related]
13. Benralizumab versus Mepolizumab for Eosinophilic Granulomatosis with Polyangiitis. Reply.
Wechsler ME; Fan Y; Merkel PA
N Engl J Med; 2024 May; 390(20):1940. PubMed ID: 38810204
[No Abstract] [Full Text] [Related]
14. Reply to "Mepolizumab in patients with eosinophilic granulomatosis with polyangiitis in remission: What is the right dose?".
Caminati M; Crisafulli E; Lunardi C; Micheletto C; Festi G; Maule M; Giollo A; Orsolini G; Senna G
J Allergy Clin Immunol Pract; 2021 Jul; 9(7):2943-2944. PubMed ID: 34246445
[No Abstract] [Full Text] [Related]
15. Eosinophilic granulomatosis with polyangiitis-related myocarditis during mepolizumab therapy reveals a Th1/Th17-mediated vasculitic response.
Bello F; Emmi G; Tamburini C; Maggi L; Annunziato F; Cosmi L; Prisco D
Clin Exp Rheumatol; 2022 May; 40(4):863-864. PubMed ID: 35485409
[No Abstract] [Full Text] [Related]
16. [Benralizumab in cases of eosinophilic granulomatosis with polyangiitis].
Carrette A; Mercier V; Lelubre C; Peché R
Rev Mal Respir; 2022 Sep; 39(7):621-625. PubMed ID: 35909008
[TBL] [Abstract][Full Text] [Related]
17. Familial Eosinophilic Granulomatosis with Polyangiitis in a Sister and Brother.
Ueki Y; Oshikata C; Asai Y; Kaneko T; Tsurikisawa N
Intern Med; 2020 Apr; 59(7):991-995. PubMed ID: 31813915
[TBL] [Abstract][Full Text] [Related]
18. Justification of the Subcutaneous Mepolizumab Dose of 300 mg in Eosinophilic Granulomatosis With Polyangiitis and Hypereosinophilic Syndrome.
Pouliquen IJ; Austin D; Steinfeld J; Yancey SW
Clin Ther; 2021 Jul; 43(7):1278-1280. PubMed ID: 34187697
[No Abstract] [Full Text] [Related]
19. Polyangiitis overlap syndrome of granulomatosis with polyangiitis (Wegener's granulomatosis) and eosinophilic granulomatosis with polyangiitis (Churg-Strauss syndrome).
Uematsu H; Takata S; Sueishi K; Inoue H
BMJ Case Rep; 2014 Feb; 2014():. PubMed ID: 24577169
[TBL] [Abstract][Full Text] [Related]
20. [Current approaches to diagnosing and treating eosinophilic granulomatosis with polyangiitis: The 2015 international guidelines].
Beketova TV; Volkov MY; Nasonov EL
Ter Arkh; 2016; 88(5):86-92. PubMed ID: 27239934
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
